Indirubin-3/'-monoxime

• CAT Number: I002044
• CAS Number: 160807-49-8
• Molecular Formula: C16H11N3O2
• Molecular Weight: 277.3
• Purity: ≥95%
• Target: GSK-3β
• Solubility: DMSO: ≥ 37 mg/mL
• Storage: -20°C
• IC50: 22 nM [1]
• InChIKey: HBDSHCUSXQATPO-BGBJRWHRSA-N

Indirubin-3′-monoxime (Cat No.:I002044) is a selective inhibitor of cyclin-dependent kinases (CDKs). It demonstrates potent inhibition with IC50 values of 0.18 μM for CDK1-cyclin B, 0.44 μM for CDK2-cyclin A, 0.25 μM for CDK2-cyclin E, 3.33 μM for CDK4-cyclin D1, and 0.065 μM for CDK5-p35. In addition to its CDK inhibitory activity, it acts as a direct and selective inhibitor of 5-lipoxygenase, with an IC50 range of 7.8-10 μM. Indirubin-3′-monoxime holds potential as a therapeutic agent for conditions involving dysregulated CDK activity and excessive 5-lipoxygenase activity.

Reference

[1]. Leclerc S, et al. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer/’s disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem. 2001 Jan 5;276(1):251-60.

[2]. Blazevic T, et al. Indirubin-3/’-monoxime exerts a dual mode of inhibition towards leukotriene-mediated vascular smooth muscle cell migration. Cardiovasc Res. 2014 Mar 1;101(3):522-32.

[3]. Sharma S, et al. Neuroprotective role of Indirubin-3/’-monoxime, a GSKβ inhibitor in high fat diet induced cognitive impairment in mice. Biochem Biophys Res Commun. 2014 Oct 3;452(4):1009-15.